Lilly direct-selling Zepbound at $499/mo — compare with 11 other programs

Ozempic in North Carolina (2026)

semaglutide · GLP-1 weight management · North Carolina-specific guide

Reviewed by the glpzoom Editorial Team against primary clinical sources — FDA labeling, peer-reviewed trials, and specialty-society guidelines.
Content current as of June 2026; updated when guidance or availability changes.
Last verified by glpzoom Editorial Team against primary sources

About Ozempic

FDA-approved semaglutide for type 2 diabetes. Widely used off-label for weight loss.

See the full Ozempic review for dosing, efficacy data, side effects, and the full pharmacy + telehealth program comparison.

Insurance coverage for Ozempic in North Carolina

North Carolina Medicaid expansion added coverage in 2024; Wegovy covered with prior authorization for BMI ≥30 + comorbidity.

CarrierOzempic statusDetail
AetnaCoveredAetna covers Ozempic broadly for type 2 diabetes. Prior auth is standard but approval is straightforward with a T2D diagnosis. Off-label weight-loss use is NOT covered.
Blue Cross Blue ShieldCoveredMost BCBS plans cover Ozempic for type 2 diabetes with prior auth. Off-label weight-loss use is generally not covered.
UnitedHealthcareCoveredUHC covers Ozempic for diabetes broadly with standard prior auth.
CignaCoveredStandard diabetes coverage with prior auth.
HumanaCoveredHumana covers Ozempic for type 2 diabetes across commercial and Medicare lines with prior auth.
Kaiser PermanenteCoveredKaiser covers Ozempic for diabetes through standard pharmacy benefit.
AnthemCoveredStandard diabetes coverage with prior auth.
MedicareCoveredMedicare Part D covers Ozempic for FDA-approved type 2 diabetes use. Most plans require prior authorization with documented T2D diagnosis.
MedicaidCoveredMost state Medicaid programs cover Ozempic for type 2 diabetes with prior authorization.
TRICARECoveredTRICARE covers Ozempic for type 2 diabetes with prior authorization.

Telehealth and prescribing in North Carolina

NC Medical Board permits interstate telehealth. IMLC member state.

Major platforms with active North Carolina availability that may prescribe Ozempic: Hims Weight Loss, Ro Body, Sequence. Each platform varies in which drugs they prescribe, insurance handling, and clinical model. See our platform comparisons for details.

Compounded Ozempic in North Carolina

NC Board of Pharmacy enforcing FDA 2026 compounding restrictions.

See our guide on the FDA compounding shutdown for the national context.

Ozempic in North Carolina — frequently asked

Is Ozempic legal in North Carolina?+

Yes. Ozempic (semaglutide) is FDA-approved and legal in all 50 US states including North Carolina. State-level differences appear in insurance coverage, telehealth prescribing rules, and (for GLP-1s) compounding pharmacy access — not in the underlying legality of the medication itself.

Can I get Ozempic via telehealth in North Carolina?+

NC Medical Board permits interstate telehealth. IMLC member state. Major US telehealth platforms operating in North Carolina that may prescribe Ozempic include Hims Weight Loss, Ro Body, Sequence. Each platform handles insurance and prescribing differently — see our platform comparisons for details.

Does North Carolina Medicaid cover Ozempic?+

North Carolina Medicaid expansion added coverage in 2024; Wegovy covered with prior authorization for BMI ≥30 + comorbidity. For Ozempic specifically: Most state Medicaid programs cover Ozempic for type 2 diabetes with prior authorization.

What's the cheapest way to get Ozempic in North Carolina?+

For Ozempic in North Carolina, the three main paths are: (1) insurance with prior authorization if your plan covers it (often $0-$25 copay), (2) manufacturer self-pay programs (NovoCare for Wegovy/Ozempic, LillyDirect for Zepbound/Mounjaro/Orforglipron), (3) telehealth bundles that include the medication. Direct-pay manufacturer programs typically beat retail pharmacy prices in 2026.

Is compounded Ozempic still available in North Carolina?+

NC Board of Pharmacy enforcing FDA 2026 compounding restrictions. The FDA proposed permanently ending large-scale 503B compounding of semaglutide and tirzepatide on April 30, 2026. Individualized 503A compounding for documented clinical need may continue in North Carolina, but routine 'cheaper alternative' compounding is being shut down.

Related

We may earn a commission when you click links to partners. Affiliate disclosure.